Biotech innovation is a high-stakes game where ideas meet funding limits. In 2025, shifting investment cycles—from the metabolic disease boom to struggles in cell and gene therapies—reshape the landscape. Macroeconomic and political forces, including U.S. research funding shifts and Europe’s fragmented capital markets, add complexity. This panel explores how investors filter opportunities, which biotech sectors rise or fall, and what it takes to secure investment.
May 5, 15:30 - 16:15, room Marriott 3+4+5
| Name | Position | Institution |
|---|---|---|
| Joris Pezzini | EVP, Biopharma | Alira Health |
| Name | Position | Institution |
|---|---|---|
| Pascale Eede | Associate | Apollo Health Ventures |
| Pierre Morgon | CEO | Ibex Therapeutics |
| Massimo Mineo | CEO | Neurolieve Biosciences |
| Kevin Hammon | Vice President | EQT Life Science |
Alira Health is a global healthcare consulting and research organization committed to making a positive impact on patients’ lives. We offer integrated services in regulatory, market access, and commercial strategy, along with full-service clinical trial management and patient-centric evidence generation. By combining strategy with execution, we empower our clients with data-driven insights, ensuring successful outcomes and measurable impact across the healthcare ecosystem.
